by LCGC-Team | Apr 22, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely... by LCGC-Team | Apr 22, 2016
ALK-Diagnostics in NSCLC – Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH) von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, Griesinger F, Dietel M, Grohé Ch Journal: Pneumologie Published: April 1st,... by LCGC-Team | Jan 11, 2016
Clinicopathological characteristics of RET rearranged lung cancer in European patients Sebastian Michels, Andreas Hans Scheel, Matthias Scheffler, Anne Maria Schultheis, Oliver Gautschi, Franziska Aebersold, Joachim Diebold, Georg Pall, Sacha Rothschild, PhD, Lukas...